Heska Corporation
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Heska Corporation Heska Corporation (HSKA), founded in 1988 and headquartered in Loveland, Colorado, develops, manufactures, markets, and supports advanced veterinary diagnostic and specialty products primarily for companion animals including canines, felines, and horses. The company offers point-of-care diagnostic laboratory instruments and consumables such as the Element i+ immunoassay platform, rapid assay diagnostic tests including the truRapid Series, clinical chemistry analyzers, and urine/fecal analyzers; digital imaging products and informatics solutions; digital cytology services via HeskaView; allergy testing and immunotherapy; single-use in-clinic tests; heartworm preventives; vaccines; practice information management software (PIMS); reference laboratory testing; and contract manufacturing of biologicals and pharmaceuticals. Heska operates through two segments, North America (United States, Canada, Mexico) and International (primarily Germany, Italy, Spain, France, Switzerland, Australia, Malaysia), serving licensed veterinarians with a focus on point-of-care diagnostics, imaging, and related services. In June 2023, Mars, Incorporated acquired Heska for $120 per share through its Antech Diagnostics subsidiary, integrating Heska into Mars Petcare's Science & Diagnostics division to expand global point-of-care veterinary diagnostics offerings, enhance R&D, and broaden access to diagnostic technologies; the HSKA ticker was subsequently delisted.
Dalan Animal Health Ships First Honey Bee Vaccine to Tauzer Apiaries, Potentially Protecting 25 Million Bees.
HESKA CORPORATION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Heska Corporation - HSKA
Heska (HSKA) Q1 Earnings and Revenues Lag Estimates
HESKA CORPORATION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Heska Corporation - HSKA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, LSI, EXR, DFFN
Why Heska Stock Is On Fire Today
HSKA STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Heska Corporation Is Fair to Shareholders
Heska Corporation (HSKA) Q4 2022 Earnings Call Transcript
Heska (HSKA) Q4 Earnings and Revenues Surpass Estimates
Heska (HSKA) Moves to Buy: Rationale Behind the Upgrade
Heska Corp's CEO Loads Up on Shares After 70% Nosedive
Heska (HSKA) Moves 9.0% Higher: Will This Strength Last?
First-in-Class Honeybee Vaccine Receives Conditional License from the USDA Center for Veterinary Biologics
Heska Corporation (HSKA) Q3 2022 Earnings Call Transcript
Heska Corp (HSKA) CEO Kevin Wilson on Q2 2022 Results - Earnings Call Transcript
5 Toxic Stocks That May Prove Hazardous for Your Portfolio
Heska Corp (HSKA) CEO Kevin Wilson on Q1 2022 Results - Earnings Call Transcript
Heska (HSKA) Misses Q1 Earnings and Revenue Estimates
VolitionRx strikes exclusive $28M deal with Heska Corp to sell its Nu.Q vet cancer screening test
Heska Corporation's (HSKA) CEO Kevin Wilson on Q4 2021 Results - Earnings Call Transcript